Reneo Pharmaceuticals, Inc. (RPHM)

Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). They are developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 is a selective peroxisome proliferator-activated receptor delta (PPARd) agonist that has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation (FAO), and may increase production of new mitochondria. They believe REN001 could benefit patients with genetic mitochondrial myopathies who experience weakness, fatigue, cramping, and wasting of muscle due to the mitochondria’s inability to produce adequate levels of ATP. These patients often struggle to perform everyday activities, and over time, are at risk of experiencing cardiac and multisystem morbidities and have reduced life expectancy. They are initially developing REN001 in three rare genetic diseases that typically present with myopathy and have high unmet medical needs: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disease type V (McArdle disease).

Industry
Pharmaceutical Preparations

CEO	CFO
Gregory J. Flesher	Vineet R. Jindal

Gregory J. Flesher has served as our President and Chief Executive Officer and a member of our board of directors since November 2020. Prior to joining us, Mr. Flesher served as the Chief Executive Officer and a member of the board of directors of Novus Therapeutics, Inc., a public specialty pharmaceutical company, from May 2017 to November 2020. Mr. Flesher previously served as Chief Executive Officer and a member of the board of directors for Otic Pharma, Ltd., a private pharmaceutical company, from July 2015 to May 2017. Mr. Flesher also served as Senior Vice President of Corporate Development and Chief Business Officer, and other executive management roles at Avanir Pharmaceuticals, Inc., a public pharmaceutical company, from 2006 to 2015. Mr. Flesher has served as a member of the board of directors for Adynxx, Inc., a pharmaceutical company, since 2019. Mr. Flesher received his B.S. in Biology from Purdue University and studied Biochemistry and Molecular Biology at Indiana University School of Medicine. We believe Mr. Flesher’s extensive senior leadership experience at numerous biopharmaceutical companies qualify him to serve on our board of directors.

Vineet R. Jindal has served as our Chief Financial Officer since March 2021. Prior to joining us, Mr. Jindal served as Vice President, Strategy and Investor Relations for Reata Pharmaceuticals, Inc., a public biopharmaceutical company, from November 2016 to March 2021. Mr. Jindal previously served as Chief Executive Officer, Co-Founder and a member of the board of directors of Stockr, Inc., a social media platform focused on connecting investors with public companies, from 2009 to 2014. Mr. Jindal also founded Bay Street Advisors, a strategic consulting firm focusing on therapeutic and capital markets, where he served from 2008 to 2010. Mr. Jindal has also served as the Managing Director and Head of Healthcare Equity Research at ThinkEquity Partners, a boutique investment bank, as the Vice President of Biotechnology Equity Research at Wedbush Morgan Securities, a financial services firm, as a Biotechnology and Specialty Pharmaceuticals Research Analyst at Origin Capital Management, an investment management firm, and as a Biotechnology Equity Research Associate at Lehman Brothers, a financial services firm. Mr. Jindal received a B.A. in Integrative Biology from the University of California, Berkeley, a M.A. in Endocrinology from the University of California, Berkeley and a M.S. in Pharmacology from Cornell University.

Employees	Founded
23	2014

Address: 12230 El Camino Real, Suite 230 San Diego, California 92130

Telephone: (858) 283-0280

Web page: http://www.reneopharma.com

First Trade Date	4/9/2021
Status	Priced
Exchange	NASDAQ
Lockup Period Expiration	.Pro
Quiet Period Expiration	.Pro
Old Price Range	-

Share prices ($)

What do you think will happen with the RPHM share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

The lead left underwriter: Jefferies

Over the last 12 months Since the beginning of the year

IPOs led by the firm	.Pro
Profitability of conducted IPOs  ?	.Pro
1st day change  ?	.Pro
Change for the first 3 months  ?	.Pro

IPOs led by the firm	.Pro
Profitability of conducted IPOs  ?	.Pro
1st day change  ?	.Pro
Change for the first 3 months  ?	.Pro

Underwriters
Jefferies/ SVB Leerink/ Piper Sandler
CO-Managers
-